BMYMP News and Press, Bristol-Myers Squibb $2Pr From 08/18/22

An all-stock portfolio is usually a risky bet for retirees due to sequence of returns risk and inflation. That said, we can arrange stocks by sectors to better prepare for bear markets and any economic environment. It's the all-weather retirement stock portfolio. An all-...

Recent headlines have claimed that Michael Burry is selling everything. But this appears to be false. His hedge fund is selling most of its positions, but Burry's personal wealth is still heavily invested in real assets as far as we know. Michael Burry is one of the most inf...

Michael Burry has sold all but one position in Scion Asset Management's portfolio. Macroeconomic conditions are setting up for a potential bottom-drop-out moment in markets. Earnings estimates are too high given forward-looking indicators. A picture is worth a thousand words, ...

Stock market expectations have shifted to a relatively more benign Federal Reserve rate outlook, thus driving a sharp rally. The market is approaching a key technical level. Healthcare has relatively outperformed the market and has been consolidating. Biotechs found a bottom a...

Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...

This article updates one I wrote in August 2021 based on a template article by David Van Knapp, written in June 2020. We both use the DVK Quality Snapshots scoring system to assess the quality of dividend growth stocks. The system employs five quality indicators from independent s...

This month I had a total of 11 transactions. I sold my positions in Power REIT and Reinsurance Group of America. I reached over €1,000 in forward dividends. In contrast to the first half a year of 2022, July was a good month when it comes to stock returns. July wa...

Be prepared for more volatility, and try to use it to your advantage. Since cash is just as important as equities according to the cash management discipline. Bid low. If you get filled great, if not you still have your precious cash. I am wary now because everyone is sure we ...

Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022. Teva Pharmaceutical has made progress in resolving opioid crisis lawsuits, reaching an ag...

Pfizer will have an outstanding 2022. 2023 will be a strong year as well. But there's not a lot of long-term growth to be expected - instead, revenue at the end of the current decade will most likely be meaningfully lower compared to 2022. Shares aren't expensive, but they aren't ...